Gene · 7301
Papers2,825
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
801 to 820 of 2,825
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Armed to the Teeth-The Oral Mucosa Immunity System and Microbiota. | Int J Mol Sci | 2022 | 35055069 | PubTator, text mining | PubMed |
| PKM2 Modulation in Head and Neck Squamous Cell Carcinoma. | Int J Mol Sci | 2022 | 35054968 | PubTator, text mining | PubMed |
| Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma. | Br J Cancer | 2022 | 35043008 | PubTator, text mining | PubMed |
| A platform of assays for the discovery of anti-Zika small-molecules with activity in a 3D-bioprinted outer-blood-retina model. | PLoS One | 2022 | 35041689 | PubTator, text mining | PubMed |
| Circ_0000467 Exerts an Oncogenic Role in Colorectal Cancer via miR-330-5p-Dependent Regulation of TYRO3. | Biochem Genet | 2022 | 35039980 | PubTator, text mining | PubMed |
| Before the "cytokine storm": Boosting efferocytosis as an effective strategy against SARS-CoV-2 infection and associated complications. | Cytokine Growth Factor Rev | 2022 | 35039221 | PubTator, text mining | PubMed |
| Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. | J Immunother | 2022 | 35034046 | PubTator, text mining | PubMed |
| Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. | Cancer Treat Rev | 2022 | 35033866 | PubTator, text mining | PubMed |
| Up-regulated serum levels of TAM receptor tyrosine kinases in a group of Egyptian autistic children. | J Neuroimmunol | 2022 | 35033774 | PubTator, text mining | PubMed |
| The role of phosphatidylserine on the membrane in immunity and blood coagulation. | Biomark Res | 2022 | 35033201 | PubTator, text mining | PubMed |
| Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer. | Signal Transduct Target Ther | 2022 | 35027529 | PubTator, text mining | PubMed |
| Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration. | Mol Cancer Res | 2022 | 35022314 | PubTator, text mining | PubMed |
| Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. | Nat Rev Cancer | 2022 | 35013601 | PubTator, text mining | PubMed |
| Virus-Mimicking Polymer Nanoparticles Targeting CD169+ Macrophages as Long-Acting Nanocarriers for Combination Antiretrovirals. | ACS Appl Mater Interfaces | 2022 | 34995059 | PubTator, text mining | PubMed |
| Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. | EBioMedicine | 2022 | 34973624 | PubTator, text mining | PubMed |
| Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment. | Arch Toxicol | 2022 | 34973110 | PubTator, text mining | PubMed |
| Immunological Aspects of AXL/GAS-6 in the Context of Human Liver Regeneration. | Hepatol Commun | 2022 | 34951136 | PubTator, text mining | PubMed |
| Proteomic analysis and miRNA profiling of human testicular endothelial cell-derived exosomes: the potential effects on spermatogenesis. | Asian J Androl | 2022 | 34916478 | PubTator, text mining | PubMed |
| Mapping the metabolomic and lipidomic changes in the bleomycin model of pulmonary fibrosis in young and aged mice. | Dis Model Mech | 2022 | 34845494 | PubTator, text mining | PubMed |
| Increased serum AXL is associated with radiographic knee osteoarthritis severity. | Int J Rheum Dis | 2022 | 34841689 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7301/papers?page=41